Literature DB >> 27378102

A prognostic model for resectable soft tissue and cutaneous angiosarcoma.

Andrew J Sinnamon1, Madalyn G Neuwirth1, Matthew T McMillan1, Brett L Ecker1, Edmund K Bartlett1, Paul J Zhang2, Rachel R Kelz1, Douglas L Fraker1, Robert E Roses1, Giorgos C Karakousis3.   

Abstract

BACKGROUND: Angiosarcoma is an aggressive tumor rising in incidence from use of therapeutic radiation. Because of its relative rarity, prognostic factors have not been clearly delineated.
METHODS: Patients who underwent resection of localized angiosarcoma from 2002 to 2012 were identified using the National Cancer Data Base. Factors associated with poor overall survival (OS) were identified using Cox proportional hazards modeling and internally validated with bootstrap resampling. These were used to construct a risk model to identify low-, intermediate-, or high-risk groups.
RESULTS: Median OS among 821 patients undergoing resection was 3.4 years. On multivariable analysis of factors known preoperatively, those associated with worse OS included: age >70 years (HR 2.02, P < 0.0001), black race (HR 1.92, P < 0.0001), head and neck primary (HR 1.44, P = 0.003), grade 3 tumor (HR 1.53, P = 0.013), size 3-7 cm (HR 1.64, P < 0.0001), size >7 cm (HR 2.37, P < 0.0001). After including postoperative variables, positive resection margins were associated with worse OS (microscopic, HR 1.59, P = 0.002; macroscopic, HR 3.38, P = 0.008). Stratification by risk group was superior to AJCC stage in discriminating OS.
CONCLUSIONS: In the largest study to date of patients with angiosarcoma, risk factors for poor OS were identified to create a clinically useful risk model that can prognosticate patients with localized disease following surgical resection. J. Surg. Oncol. 2016;114:557-563.
© 2016 Wiley Periodicals, Inc. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  angiosarcoma; prognosis; risk factor; survival

Mesh:

Year:  2016        PMID: 27378102     DOI: 10.1002/jso.24352

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

Review 1.  Management of Cutaneous Angiosarcoma: an Update Review.

Authors:  Siwei Bi; Ai Zhong; Xiya Yin; Jingyi Li; Ying Cen; Junjie Chen
Journal:  Curr Treat Options Oncol       Date:  2022-02-19

2.  Characteristics and Prognosis of Primary Head and Neck Angiosarcomas: A Surveillance, Epidemiology, and End Results Program (SEER) Analysis of 1250 Cases.

Authors:  Kevin C Lee; Sung-Kiang Chuang; Elizabeth M Philipone; Scott M Peters
Journal:  Head Neck Pathol       Date:  2018-10-24

3.  Two cases of radiation-associated angiosarcoma of the breast.

Authors:  Yuki Nomoto; Yuko Kijima; Yoshiaki Shinden; Munetugu Hirata; Yuka Eguchi; Heiji Yoshinaka; Ikumi Kitazono; Tsubasa Hiraki; Akihide Tanimoto; Shoji Natsugoe
Journal:  Surg Case Rep       Date:  2018-11-13

4.  Prognostic Factors in a Large Nationwide Cohort of Histologically Confirmed Primary and Secondary Angiosarcomas.

Authors:  Marije E Weidema; Uta E Flucke; Winette T A van der Graaf; Vincent K Y Ho; Melissa H S Hillebrandt-Roeffen; Yvonne M H Versleijen-Jonkers; Olga Husson; Ingrid M E Desar
Journal:  Cancers (Basel)       Date:  2019-11-12       Impact factor: 6.639

Review 5.  Cutaneous Angiosarcoma: The Possibility of New Treatment Options Especially for Patients with Large Primary Tumor.

Authors:  Yasuhiro Fujisawa; Koji Yoshino; Taku Fujimura; Yoshiyuki Nakamura; Naoko Okiyama; Yosuke Ishitsuka; Rei Watanabe; Manabu Fujimoto
Journal:  Front Oncol       Date:  2018-03-02       Impact factor: 6.244

Review 6.  Cutaneous angiosarcoma: update on biology and latest treatment.

Authors:  Yoshihiro Ishida; Atsushi Otsuka; Kenji Kabashima
Journal:  Curr Opin Oncol       Date:  2018-03       Impact factor: 3.645

7.  Survival predictors of metastatic angiosarcomas: a surveillance, epidemiology, and end results program population-based retrospective study.

Authors:  Shihong Ren; Yucheng Wang; Zhan Wang; Jinxiang Shao; Zhaoming Ye
Journal:  BMC Cancer       Date:  2020-08-18       Impact factor: 4.430

8.  Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study.

Authors:  Anastasia Constantinidou; Nicolas Sauve; Silvia Stacchiotti; Jean-Yves Blay; Bruno Vincenzi; Giovanni Grignani; Piotr Rutkowski; Michele Guida; Nadia Hindi; Alexander Klein; Valentin Thibaud; Jozef Sufliarsky; Ingrid Desar; Neeltje Steeghs; Saskia Litiere; Hans Gelderblom; Robin L Jones
Journal:  ESMO Open       Date:  2020-08

9.  Successful treatment of primary cutaneous angiosarcoma of the nose with sequential chemo- and radiotherapy.

Authors:  H Herrscher; M Bronnec; D Antoni; J-P Ghnassia; P Magnenet; J-E Kurtz; G Noël
Journal:  Clin Transl Radiat Oncol       Date:  2019-11-21

10.  PropAngio study protocol: a neoadjuvant trial on the efficacy of propranolol monotherapy in cutaneous angiosarcoma-a proof of principle study.

Authors:  Kimberley M Heinhuis; Nikki S IJzerman; Anne Miek Koenen; Winette T A van der Graaf; Rick L Haas; Jos H Beijnen; Alwin D R Huitema; Winan J van Houdt; Neeltje Steeghs
Journal:  BMJ Open       Date:  2020-09-10       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.